Avid Bioservices Inc. (CDMO)
NASDAQ (CM) NASDAQ (CM) Primary 
The Schall Law Firm Urges Stockholders To Take Part In An Inquiry Into Avid Bioservices Inc's Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Lifecore Biomedical: An Interesting CDMO Pure Play
Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production capacity, enhancing financial performance, and attracting new customers with advanced technology and strategic investments. Despite a challenging Q1, Lifecore anticipates significant revenue growth and improved EBITDA in H2 FY25, driven by increased capacity utilization and cost management.
Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2025 Earnings Conference Call September 9, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Group Paul Knight - KeyBanc Capital Markets Max Smock - William Blair Operator Good day and thank you for standing by. Welcome to the Avid Bioservices First Quarter Fiscal Year 2025 Financial Results Conference Call.
Avid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2024 Earnings Conference Call July 2, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President & CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Jacob Johnson - Stephens Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Max Smock - William Blair Operator Thank you for standing by, and welcome to the Avid Bioservices Fourth Quarter Fiscal Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
